Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies

Translational Modeling of Anticancer Efficacy to Predict Clinical Outcomes in a First-in-Human Phase 1 Study of MDM2 Inhibitor HDM201

(2021) Nelson Guerreiro et al.   AAPS Journal

The role of TP53 in acute myeloid leukemia: Challenges and opportunities

(2019) Karina Barbosa et al.   GENES CHROMOSOMES & CANCER

In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor

(2018) Andrea Vaupel et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Dose and schedule determine distinct molecular mechanisms underlying the efficacy of the p53-MDM2 inhibitor HDM201

(2018) Sébastien Jeay et al.   CANCER RESEARCH

Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors

(2017) Andrew J. Wagner et al.   JOURNAL OF CLINICAL ONCOLOGY

MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer

(2017) Veronica Tisato et al.   Journal of Hematology & Oncology

A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer

(2016) R.T. Penson et al.   GYNECOLOGIC ONCOLOGY

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

(2015) Philipp Holzer et al.   JOURNAL OF MEDICINAL CHEMISTRY

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097

(2015) E. Weisberg et al.   MOLECULAR CANCER THERAPEUTICS

The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents

(2015) J. Canon et al.   MOLECULAR CANCER THERAPEUTICS

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

(2015) Sébastien Jeay et al.   eLife

Clinical Grade “SNaPshot” Genetic Mutation Profiling in Multiple Myeloma

(2015) Elizabeth O'Donnell et al.   EBioMedicine

SAR405838: An Optimized Inhibitor of MDM2-p53 Interaction That Induces Complete and Durable Tumor Regression

(2014) S. Wang et al.   CANCER RESEARCH

Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment

(2014) Yujun Zhao et al.   JOURNAL OF MEDICINAL CHEMISTRY

Drugging the p53 pathway: understanding the route to clinical efficacy

(2014) Kian Hoe Khoo et al.   NATURE REVIEWS DRUG DISCOVERY

MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models

(2013) C. Tovar et al.   CANCER RESEARCH

Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis

(2013) Camelia Iancu-Rubin et al.   EXPERIMENTAL HEMATOLOGY

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

(2012) Isabelle Ray-Coquard et al.   LANCET ONCOLOGY

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Identification of spliced variants of the proto-oncogene hdm2 in colorectal cancer

(2011) Zhiwei Yu et al.   CANCER

SNaPshot and StripAssay as Valuable Alternatives to Direct Sequencing for KRAS Mutation Detection in Colon Cancer Routine Diagnostics

(2011) Arantza Fariña Sarasqueta et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

E2F1-dependent oncogenic addiction of melanoma cells to MDM2

(2011) M Verhaegen et al.   ONCOGENE

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3

(2011) M H Aziz et al.   ONCOGENE

Targeted therapies for non-clear renal cell carcinoma

(2010) Eric A. Singer et al.   Targeted Oncology

Parallel sequencing used in detection of mosaic mutations: Comparison with four diagnostic DNA screening techniques

(2009) Anna Rohlin et al.   HUMAN MUTATION

TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use

(2009) M. Olivier et al.   Cold Spring Harbor Perspectives in Biology